Zevra Therapeutics, a rare disease company melding science, data and patient need to create transformational therapies for diseases with limited or no treatment options, agreed to acquire Acer Therapeutics, a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases, for $91m. “We believe that Acer’s portfolio of rare disease programs, including the recent US commercial approval of OLPRUVA for UCDs, is a perfect strategic fit for Zevra and creates significant opportunity for us to positively impact patient lives while creating shareholder value. We are excited about Acer’s clinical programs and are confident in the potential of OLPRUVA to bring UCD patients a more convenient and cost-effective treatment option over current therapies. Acer would bring unique rare disease operations and capabilities that would serve as a foundation to support the commercialization of Zevra’s pipeline as it advances," Joshua Schafer, Zevra Chief Commercialization Officer and Executive Vice President of Business Development.